Get started
Xenon Pharmaceuticals Inc.Xenon Pharmaceuticals Inc.Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

XENE chart


Full chart

XENE upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.19 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.81 USD
Net income (FY)
‪−182.39 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪73.28 M‬
Beta (1Y)
1.10

Employees


Employees (FY)
259
Change (1Y)
+46 +21.60%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−704.22 K‬ USD

About Xenon Pharmaceuticals Inc.


Sector
Health Technology
CEO
Ian C. Mortimer
Headquarters
Burnaby
Website
xenon-pharma.com
Founded
1996
FIGI
BBG0073DM784
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

XENE news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of XENE is 42.97 USD — it has increased by 2.60% in the past 24 hours. Watch Xenon Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Xenon Pharmaceuticals Inc. stocks are traded under the ticker XENE.
XENE stock has risen by 1.99% compared to the previous week, the month change is a −5.04% fall, over the last year Xenon Pharmaceuticals Inc. has showed a 12.11% increase.
We've gathered analysts' opinions on Xenon Pharmaceuticals Inc. future price: according to them, XENE price has a max estimate of 65.00 USD and a min estimate of 46.00 USD. Watch XENE chart and read a more detailed Xenon Pharmaceuticals Inc. stock forecast: see what analysts think of Xenon Pharmaceuticals Inc. and suggest that you do with its stocks.
XENE reached its all-time high on Mar 1, 2024 with the price of 50.99 USD, and its all-time low was 2.10 USD and was reached on Nov 16, 2017. View more price dynamics on XENE chart.
See other stocks reaching their highest and lowest prices.
XENE stock is 4.13% volatile and has beta coefficient of 1.10. Track Xenon Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is Xenon Pharmaceuticals Inc. there?
Today Xenon Pharmaceuticals Inc. has the market capitalization of ‪3.28 B‬, it has increased by 0.12% over the last week.
Yes, you can track Xenon Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Xenon Pharmaceuticals Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
XENE earnings for the last quarter are −0.81 USD per share, whereas the estimation was −0.82 USD resulting in a 0.69% surprise. The estimated earnings for the next quarter are −0.85 USD per share. See more details about Xenon Pharmaceuticals Inc. earnings.
Xenon Pharmaceuticals Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach ‪357.14 K‬ USD.
XENE net income for the last quarter is ‪−62.79 M‬ USD, while the quarter before that showed ‪−57.92 M‬ USD of net income which accounts for −8.40% change. Track more Xenon Pharmaceuticals Inc. financial stats to get the full picture.
No, XENE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 12, 2024, the company has 259.00 employees. See our rating of the largest employees — is Xenon Pharmaceuticals Inc. on this list?
Like other stocks, XENE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Xenon Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Xenon Pharmaceuticals Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Xenon Pharmaceuticals Inc. stock shows the buy signal. See more of Xenon Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.